PDCD1 and neoplasm: Over the past five years, immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1) and its ligand (PD-L1) have demonstrated the ability to relieve immune suppressive phenotype and achieve durable objective responses in trials of patients with metastatic disease, with the promise of changing the therapeutic landscape and improving survival outcomes for patients with this tumor (5).